AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Glycosylphosphatidylinositol anchor attachment 1 protein including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Glycosylphosphatidylinositol anchor attachment 1 protein therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Glycosylphosphatidylinositol anchor attachment 1 protein, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Glycosylphosphatidylinositol anchor attachment 1 protein. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Glycosylphosphatidylinositol anchor attachment 1 protein. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Glycosylphosphatidylinositol anchor attachment 1 protein includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Glycosylphosphatidylinositol anchor attachment 1 protein
partner:
Reaxense
upacc:
O43292
UPID:
GPAA1_HUMAN
Alternative names:
GAA1 protein homolog
Alternative UPACC:
O43292; Q9NSS0; Q9UQ31
Background:
The Glycosylphosphatidylinositol anchor attachment 1 protein (GAA1 protein homolog), encoded by the gene with accession number O43292, plays a pivotal role in the post-translational modification of proteins. It is a crucial component of the GPI transamidase complex, essential for the transfer of GPI to proteins, a process necessary for their anchoring to the cell membrane. This protein acts at a critical juncture before or during the formation of the carbonyl intermediate, highlighting its indispensable role in GPI-anchoring but not in GPI synthesis itself.
Therapeutic significance:
GAA1 protein homolog is directly implicated in Glycosylphosphatidylinositol biosynthesis defect 15, a disorder marked by severe neurological manifestations including delayed psychomotor development, intellectual disability, and early-onset seizures. Understanding the role of Glycosylphosphatidylinositol anchor attachment 1 protein could open doors to potential therapeutic strategies aimed at alleviating or managing the symptoms associated with this autosomal recessive disorder.
